Paradigm Biopharma’s clinical trials in fast lane
SYDNEY: Paradigm Biopharmaceuticals (ASX: PAR) is surpassing its own expectations in recruiting patients for its
SYDNEY: Paradigm Biopharmaceuticals (ASX: PAR) is surpassing its own expectations in recruiting patients for its
FEATURED
One in three grandparents regularly babysit their grandkids
Carers increasingly socially isolated and highly distressed claims reveals
Development to be model for extremely affordable senior housing
Developers shake up build-to-rent holdings as sector fires
Drones now fly blood samples in skies for first time
Affordable towns not set to face influx of over-65s
INNOVATION
